Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Can Exagen (NASDAQ:XGN) Keep Lifting Test Prices After 14 Straight Quarters of Gains to USD 451?

Gross profit was USD 10.84 million, aMarginof about 58.8% (calculated), compared with USD 10.08 million, or about 58.4%. Management described the margin as just under 59%. Total operating expenses rose to USD 15.2 million from USD 13.2 million, including more than USD 600,000 of …

Vinay Lochav | 12 November 2026

Why Did Xilio Therapeutics (NASDAQ:XLO) Revenue Fall to USD 10.0 Million as Its Net Loss Narrowed?

Key HighlightsCollaboration and licenseRevenuefor the third quarter of 2026 was USD 10.0 million, down from USD 19.1 million a year earlier, because less revenue was recognized under the AbbVie and Gilead agreements.The net loss narrowed to USD 5.9 million, or USD 0.30 per share, …

Vinay Lochav | 12 November 2026

What Pushed Xanadu Quantum Technologies (NASDAQ:XNDU) to a USD 26.3 Million Adjusted EBITDA Loss?

Key HighlightsAdjusted EBITDA loss was USD 26.3 million in the third quarter of 2026, against USD 21.3 million in the second quarter and USD 15.4 million a year earlier, driven mainly by higherResearch and Developmentspending.Net loss was USD 32.2 million compared with USD 42.1 …

Vinay Lochav | 12 November 2026

Why Did a USD 59.1 Million Profit Sit Beside Losses at Arbutus Biopharma (NASDAQ:ABUS), ABVC BioPharma (NASDAQ:ABVC), Alpha Cognition (NASDAQ:ACOG) and Alto Neuroscience (NYSE:ANRO)?

Key HighlightsArbutus Biopharma (NASDAQ:ABUS) reported third-quarterNet Incomeof USD 59.1 million onRevenueof only USD 0.3 million, after a USD 67.3 millionDividendfrom Genevant.ABVC BioPharma (NASDAQ:ABVC) cut its third-quarter net loss 33% to USD 1.39 million with zero revenue, while its filing states substantial doubt about continuing …

Vinay Lochav | 12 November 2026

How Far Apart Are Cash Pools of USD 315.3 Million at BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and USD 9.9 Million at Atara Biotherapeutics (NASDAQ:ATRA), With Atossa Therapeutics (NASDAQ:ATOS) and Black Diamond Therapeutics (NASDAQ:BDTX) in Between?

Key HighlightsAtossa Therapeutics (NASDAQ:ATOS) held USD 20.6 million of cash at September 30, 2026, and its filing says existing resources are likely insufficient for the next 12 months.Atara Biotherapeutics (NASDAQ:ATRA) reported USD 9.9 million of cash and short-term investments and a March 31, 2027 …

Vinay Lochav | 12 November 2026

Is USD 503.5 Million at Braveheart Bio (NASDAQ:BRVE) the Outlier Among Biomea Fusion (NASDAQ:BMEA), CalciMedica (NASDAQ:CALC) and Boundless Bio (NASDAQ:BOLD)?

Key HighlightsBiomea Fusion (NASDAQ:BMEA) cut its third-quarter net loss to USD 6.2 million from USD 16.4 million, with USD 26.8 million of cash funding operations only into the second quarter of 2027.Boundless Bio (NASDAQ:BOLD) expects a specialCash Dividendof about USD 44 million to USD …

Vinay Lochav | 12 November 2026

Can a 9 to 3 Panel Vote Against Capricor Therapeutics (NASDAQ:CAPR) Be Overcome While Cullinan Therapeutics (NASDAQ:CGEM), Cellectar Biosciences (NASDAQ:CLRB) and Context Therapeutics (NASDAQ:CNTX) Await Their Own Milestones?

Key HighlightsCapricor Therapeutics (NASDAQ:CAPR) faces a November 22, 2026 FDA target date for deramiocel after an advisory committee voted 3 in favor and 9 against on cardiomyopathy evidence in July.Cullinan Therapeutics (NASDAQ:CGEM) initiated a New Drug Application for zipalertinib in October 2026 and held …

Vinay Lochav | 12 November 2026

What Separates USD 430.2 Million at Hemab Therapeutics (NASDAQ:COAG) From Coya Therapeutics (NASDAQ:COYA), Corbus Pharmaceuticals (NASDAQ:CRBP) and Cumberland Pharmaceuticals (NASDAQ:CPIX)?

Key HighlightsHemab Therapeutics (NASDAQ:COAG) held USD 430.2 million of cash, cash equivalents and marketable securities at September 30, 2026, which management said funds operations into 2029.Coya Therapeutics (NASDAQ:COYA) held USD 35.8 million of cash, and its filing states substantial doubt about continuing as a …

Vinay Lochav | 12 November 2026

Why Did a USD 96.2 Million Warrant Loss Hit Gossamer Bio (NASDAQ:GOSS) While Gain Therapeutics (NASDAQ:GANX), Humacyte (NASDAQ:HUMA) and iBio (NASDAQ:IBIO) Watch Cash?

Key HighlightsGain Therapeutics (NASDAQ:GANX) reported a USD 3.2 million third quarter net loss and USD 11.7 million of cash, and management flagged substantial doubt about continuing as a going concern.Gossamer Bio (NASDAQ:GOSS) booked a USD 96.2 million loss on issuing warrants, which left other …

Vinay Lochav | 12 November 2026

How Did Inovio Pharmaceuticals (NASDAQ:INO) Lose USD 49.2 Million While SeaStar Medical (NASDAQ:ICU), Inhibikase Therapeutics (NASDAQ:IKT) and MiNK Therapeutics (NASDAQ:INKT) Race to Fund Trials?

Key HighlightsInovio Pharmaceuticals (NASDAQ:INO) reported a USD 49.2 million net loss, of which USD 26.9 million was a non-cashWarrantLiabilitychange, while loss from operations narrowed to USD 19.5 million.SeaStar Medical (NASDAQ:ICU) said netRevenuewas about USD 635,000, up 247%, with cash of about USD 4 million …

Vinay Lochav | 12 November 2026
Support

Hi! How can we help you today?

Loading…